title: Comparative randomized pilot study of azithromycin and doxycycline efficacy and tolerability in the treatment of prostate infection caused by Ureaplasma urealyticum.
abstract: A total of 1,442 patients with symptoms of chronic prostatitis were examined over a 4-year period at the Outpatient Department for Urogenital Infections, University Hospital for Infectious Diseases Dr. Fran Mihaljević, Zagreb, Croatia. The inclusion criteria for chronic prostatitis caused by Ureaplasma urealyticum were the presence of clinical symptoms, presence of U. urealyticum in expressed prostatic secretion (EPS) or voided urine collected immediately after prostatic massage (VB(3)), absence of U. urealyticum in urethral swabs and absence of other possible pathogens of chronic prostatitis in EPS or VB(3). A total of 63 patients with prostate infection caused by U. urealyticum were available for this pilot study. The patients were randomized according to a computer randomization list to receive a total dose of 4.5 g of azithromycin given as a 3-day therapy of 1 x 500 mg weekly for 3 weeks or doxycyline 100 mg b.i.d. for 21 days. Patients' sexual partners were treated at the same time. Clinical efficacy and tolerability of the administered drug as well as possible adverse events were evaluated during, at the end and 4-6 weeks after completion of therapy. Bacteriological efficacy was evaluated 4-6 weeks after completion of therapy. Treatment groups did not differ regarding age, distribution of urethral, prostatic, sexual and other symptoms, or digitorectal prostatic examination. Five patients treated with doxycycline had nausea. In the group of patients with prostate infection caused by U. urealyticum, the eradication rate was not significantly different with regard to the administered azithromycin (25/32) or doxycycline (23/31). Clinical cure did not significantly differ with regard to the administered azithromycin (22/32) or doxycycline (21/31).
authors.affiliation: University Hospital for Infectious Diseases Dr. Fran Mihaljević, Zagreb, Croatia. bfm@bfm.hr
authors.forename: Visnja
authors.initials: V
authors.lastname: Skerk
authors.forename: Ivana
authors.initials: I
authors.lastname: Mareković
authors.forename: Leo
authors.initials: L
authors.lastname: Markovinović
authors.forename: Josip
authors.initials: J
authors.lastname: Begovac
authors.forename: Vedrana
authors.initials: V
authors.lastname: Skerk
authors.forename: Neven
authors.initials: N
authors.lastname: Barsić
authors.forename: Vida
authors.initials: V
authors.lastname: Majdak-Gluhinić
mesh_terms: D000328:Adult; D017963:Azithromycin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004318:Doxycycline / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010865:Pilot Projects; D016869:Ureaplasma Infections / Q000188:drug therapy* / Q000382:microbiology; D016990:Ureaplasma urealyticum / Q000187:drug effects* / Q000502:physiology
chemical_list: D017963:Azithromycin; D004318:Doxycycline